Currently, several approaches exist to discover and mature therapeutic antibodies. However, all current approaches require the use of multiple expression hosts (e.g., mouse, E.coli, CHO, NS0) and several reformatting steps between hosts which compromises both quality and speed.

Adimab has taken antibody discovery to a new level of integration resulting in unprecedented speed from target to therapeutic lead. Adimab's technology is based on a strategic view of the antibody discovery process and was engineered around clearly articulated design metrics:

- Achieving maximum integration of all aspects of antibody discovery, from library design to manufacturing - Accelerating development timelines from target to therapeutic antibody - Developing presentation and screening technologies that can probe relevant aspects of antibody quality (e.g., binding affinity, effector function, ability to produce at high titer, etc.) - Reducing complexity by minimizing the number of hosts involved in the entire discovery, maturation and production process - Minimizing third party royalty obligations - Eliminating "blind spots" present in most commercial libraries, resulting from tolerance to human targets

Whereas human B-cell/hybridoma cell lines take days to generate a measurable readout, Adimab's fully synthetic, yeast-based, immune system provides a readout in hours resulting in a vastly accelerated discovery and maturation cycle.